The Nordic AML Group (NAMLG) aim to foster excellence in research and clinical care in acute myeloid leukemia (AML) in the Nordic countries, by forming an active network of clinicians and basic and translational scientists with deep interest and experience in the field.
Photo: NASA
.
[News? Please, let us know via namlgewg@gmail.com.]
Results from the Finnish VenEx trial (NCT04267081) have now been published in Blood. You can find the publication by using this link.
[Have an event? Please, let us know via namlgewg@gmail.com.]
For Nordic AML physicians attending the Acute Leukemia Symposium ISALXIX in Munich 16-19th March 2025, You are cordially invited to a NAMLG Lunch Meeting in on Monday March 17th, 12.00-14.00. […]
Find out more »The newly established Jebsen Centre for Myeloid Blood Cancer (c-myc) will have their first Annual c-myc Seminar as a full-day satellite to CCBIO’s 13th Annual Symposium and will showcase recent […]
Find out more »CCBIO has the pleasure of inviting you to the 13th CCBIO Annual Symposium May 13-14, and now, PREFINAL PROGRAM is available. To participate, please register within April 1. There will be a strong scientific […]
Find out more »The Educational Working Group is planning an "AML Course Day" in conjunction with the Nordic AML Meeting in Bergen 2025. The AML Course Day covers topics such as the current […]
Find out more »Save the dates for the upcoming Nordic AML Meeting in Bergen, Norway, 2025.
Find out more »Click here to add your own text
